ATRi Transition Rollover Study
About the study
The main purpose of the study is to monitor the safety of participant receiving long-term treatment of M6620 as monotherapy or in combination with carboplatin and paclitaxel.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Participants ongoing treatment in Vertex study VX13-970-002.
- Participant must be able to understand and provide written informed consent.
- Participant must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive guidelines, and other study procedures.
EXCLUSION CRITERIA
Exclusion Criteria:
Participants experiencing disease progression or unacceptable toxicity at the time of transition into the this study.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Advanced Stage Solid Tumors
Phase
Phase 1
Participants needed
1
Est. Completion Date
Dec 15, 2023
Treatment type
Interventional
Sponsor
Merck KGaA, Darmstadt, Germany
ClinicalTrials.gov identifier
NCT03309150
Study number
MS201923-0007
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?